Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Colorcon
McKinsey
Merck
Mallinckrodt

Last Updated: February 3, 2023

Ripretinib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for ripretinib and what is the scope of patent protection?

Ripretinib is the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ripretinib has sixty-one patent family members in thirteen countries.

One supplier is listed for this compound.

Summary for ripretinib
International Patents:61
US Patents:10
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 24
Clinical Trials: 9
Patent Applications: 80
What excipients (inactive ingredients) are in ripretinib?ripretinib excipients list
DailyMed Link:ripretinib at DailyMed
Recent Clinical Trials for ripretinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Theseus PharmaceuticalsPhase 1/Phase 2
Deciphera Pharmaceuticals LLCPhase 1/Phase 2
RenJi HospitalN/A

See all ripretinib clinical trials

US Patents and Regulatory Information for ripretinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ripretinib

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Deciphera Pharmaceuticals (Netherlands) B.V. Qinlock ripretinib EMEA/H/C/005614
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Authorised no no yes 2021-11-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ripretinib

Country Patent Number Title Estimated Expiration
Australia 2020417282 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea See Plans and Pricing
China 115135308 非晶型激酶抑制剂制剂及其使用方法 See Plans and Pricing
Argentina 122355 COMPOSICIONES DE 1-(4-BROMO-5-(1-ETIL-7-(METILAMINO)-2-OXO-1,2- DIHIDRO-1,6-NAFTIRIDIN-3-YL)-2-FLUOROFENIL)-3-FENILUREA See Plans and Pricing
South Korea 20090067175 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES See Plans and Pricing
South Korea 101110530 See Plans and Pricing
European Patent Office 2063897 INHIBITEURS DE KINASES UTILES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES (KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES) See Plans and Pricing
China 101516379 Kinase inhibitors useful for the treatment of proliferative diseases See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Merck
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.